Nurix Therapeutics (NRIX) Stock Chart & Stock Price History $9.58 -0.15 (-1.54%) As of 04:00 PM Eastern Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Nurix Therapeutics Stock Price Performance The Nurix Therapeutics (NRIX) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 35.92%, with a year-to-date return of -49.15%. In the past month, the stock has decreased 2.74%, reflecting recent market activity. As of the latest close, Nurix Therapeutics traded at $9.73 with a market cap of $741.78 million and volume of 534,374 shares. Receive NRIX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Nurix Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+0.84%1 Month Performance-2.74%3 Month Performance-45.54%Year-To-Date Performance-49.15%1 Year Performance-35.92% NRIX Stock Chart for Wednesday, May, 14, 2025 NRIX Chart by TradingView Nurix Therapeutics Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization05/13/2025$10.18$9.73-4.42%$10.26$9.70534,374 shs$741.78 million05/12/2025$9.50$10.18+7.16%$10.38$9.82807,599 shs$776.08 million05/09/2025$9.64$9.50-1.45%$10.03$9.50575,746 shs$724.24 million05/08/2025$9.30$9.64+3.66%$9.88$9.021.08 million shs$734.92 million05/07/2025$9.65$9.30-3.63%$9.71$9.201.25 million shs$709.00 million05/06/2025$10.94$9.65-11.79%$10.86$9.64680,832 shs$735.68 million05/05/2025$11.27$10.94-2.93%$11.17$10.73525,663 shs$834.02 million05/02/2025$11.16$11.27+0.99%$11.56$11.18599,966 shs$859.18 million05/01/2025$11.53$11.16-3.21%$11.52$11.11692,035 shs$850.79 million04/30/2025$11.44$11.53+0.79%$11.72$11.05747,531 shs$879.00 million Get the Latest News and Ratings for NRIX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Nurix Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 04/29/2025$11.47$11.44-0.26%$11.66$11.29548,431 shs$872.14 million04/28/2025$11.56$11.47-0.78%$11.72$11.25784,359 shs$874.43 million04/25/2025$11.52$11.56+0.35%$11.73$11.21589,138 shs$881.29 million04/24/2025$11.61$11.52-0.78%$11.75$11.28838,277 shs$878.24 million04/23/2025$11.46$11.61+1.31%$12.38$11.552.51 million shs$885.10 million04/22/2025$10.55$11.46+8.63%$11.51$10.681.15 million shs$873.67 million04/21/2025$10.24$10.55+3.03%$10.96$9.921.32 million shs$804.29 million04/18/2025$10.24$10.24$10.27$9.521.32 million shs$780.66 million04/17/2025$9.80$10.24+4.49%$10.27$9.521.32 million shs$780.66 million04/16/2025$9.82$9.80-0.20%$10.02$9.231.06 million shs$747.11 million04/15/2025$9.85$9.82-0.30%$10.17$9.63785,041 shs$748.64 million04/14/2025$9.14$9.85+7.77%$9.97$9.17998,502 shs$750.93 million Related Companies VKTX Stock Price Chart PTCT Stock Price Chart CRNX Stock Price Chart SRRK Stock Price Chart MRUS Stock Price Chart CPRX Stock Price Chart XENE Stock Price Chart MOR Stock Price Chart PTGX Stock Price Chart MLTX Stock Price Chart Receive NRIX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Nurix Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:NRIX) was last updated on 5/14/2025 by MarketBeat.com Staff From Our PartnersSilver Demand Is Soaring-Supply Can't Keep UpSilver demand hit 1.16 billion ounces in 2024-while supply fell short again for the fourth year in a row. I...i2i Marketing Group, LLC | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | Sponsored“America is running out of power” - The Washington PostAccording to The Washington Post, AI is causing America to “run out of power”... It’s true — utility compan...True Market Insiders | SponsoredTrump Made a Deal. Your Retirement Could Still Be in Danger.America is still barreling toward a financial cliff. This isn't political. It's mathematical. And no trade ...Lear Capital | SponsoredBITCOIN Liquidity pools are the backbone of crypto—and right now, they’re exploding with activity. By providing liqui...Awesomely, LLC | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nurix Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nurix Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.